Effect of the COVID-19 pandemic on outpatient care and rehabilitation in neuromuscular clinical practice in Japan: a health insurance claims database analysis
Source : https://bmjopen.bmj.com/content/13/6/e070818
Objectives To evaluate the impact of the COVID-19 pandemic on outpatient care in Japanese patients with neuromuscular diseases (NMDs). Design This retrospective cohort study included patients between January 2018 and...
Conclusions: Outpatient consultation and rehabilitation visits during the COVID-19 pandemic were affected in Japanese patients with NMDs. Longer-term evaluations are required to understand if these reductions in outpatient care would affect patient prognosis.
Retracted: miR-181a Ameliorates the Progression of Myasthenia Gravis by Regulating TRIM9
Source : https://www.hindawi.com/journals/ecam/2023/9861015/
Retracted: miR-181a Ameliorates the Progression of Myasthenia Gravis by Regulating TRIM9
Relevance: This article has been retracted by Hindawi following an investigation undertaken by the publisher.
Efgartigimod Alfa in Generalised Myasthenia Gravis: A Profile of Its Use - CNS Drugs
Source : https://link.springer.com/article/10.1007/s40263-023-01000-z
Intravenous efgartigimod alfa (also known as efgartigimod alfa-fcab in the USA; Vyvgart®) is the first neonatal Fc receptor antagonist approved in several countries worldwide, including the USA and EU for...
Conclusions/Relevance: The clinical benefits of efgartigimod alfa were durable and reproducible. Furthermore, in an interim analysis of the ongoing open-label phase 3 ADAPT+ extension trial, efgartigimod alfa provided consistent clinically meaningful improvements in patients with gMG. Efgartigimod alfa was generally well tolerated, with most...
Physician- and patient-reported perspectives on myasthenia gravis in Europe: a real-world survey - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37386469/
Our findings demonstrated the high burden of MG despite current treatment options for patients with MG.
Conclusions: Our findings demonstrated the high burden of MG despite current treatment options for patients with MG.
Summary of Research: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis - Neurology and Therapy
Source : https://link.springer.com/article/10.1007/s40120-023-00514-4
This article provides a summary of a previously published paper: Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. The paper reported the results of the CHAMPION-MG trial which investigated the...
Conclusions/Relevance: Ravulizumab improved symptoms and muscle strength compared with placebo in patients with gMG who had acetylcholine receptor antibodies, and its side effects were mild in most patients.